Aethlon Medical, Inc. — Form 10-Q Summary
Business context and reporting period. This filing covers the quarter and six months ended September 30, 2021, Aethlon’s fiscal second quarter, and was signed November 9, 2021. Aethlon is a clinical-stage medical technology company developing the Hemopurifier for cancer and life-threatening viral infections; its majority-owned Exosome Sciences subsidiary focuses on diagnostics. The device has FDA Breakthrough Device designations, but is not described as an approved commercial product.
Financial performance and position
| Metric | Three months ended Sept. 30, 2021 | Six months ended Sept. 30, 2021 | Comparable 2020 period |
|---|---|---|---|
| Revenue | $131,966 | $263,932 | $0 |
| Operating expenses | $2,140,770 | $4,371,174 | $1,771,389 quarter; $3,182,535 six months |
| Net loss | $2,008,804 | $4,107,242 | $1,771,389 quarter; $3,182,535 six months |
| Loss per share, basic and diluted | $(0.13) | $(0.29) | $(0.15) quarter; $(0.29) six months |
| Net cash used in operations | $3,949,961 for six months | $2,328,901 for six months |
- Quarterly revenue comprised government contract revenue; there were no reported commercial product sales. Revenue included amounts recognized after previously missed contract milestones were achieved.
- Six-month operating expenses rose 37.3%, while net loss rose about 29.0%. In the quarter, expenses rose 20.9% and net loss rose about 13.4%. Higher payroll, hiring, CEO bonus and stock compensation, rent, insurance, and government-contract subcontractor costs contributed to the increases.
- Cash was $23.22 million at September 30, up from $9.86 million at March 31, 2021. Working capital was $22.59 million, compared with $8.98 million at March 31. Current liabilities were $974,349; total liabilities were also $974,349. The filing reports no borrowing or long-term debt balance.
- Six-month investing cash use was $78,861. Financing provided $17.39 million, primarily from equity issuance and warrant exercises. The resulting net cash increase was $13.36 million.
- Total assets were $23.87 million and stockholders’ equity was $22.90 million at September 30. Common shares outstanding increased from 12.15 million at March 31 to 15.40 million at September 30.
- Gross profit and conventional operating margins are not meaningful measures for this development-stage business; the filing presents no cost-of-revenue line.
Material changes, outlook, and risks
- Funding and dilution: Aethlon raised $4.95 million net through its at-the-market program and $11.66 million net in a registered direct offering, and received $820,938 from cash warrant exercises during the six months. No further sales were available under the described ATM agreement. These financings materially increased cash and share count.
- Management outlook: Management expected September 30 cash to fund operations for at least 12 months from the financial statements’ issuance date. It also expected continuing net losses and negative operating cash flow for the foreseeable future, with future capital needs dependent on clinical, regulatory, manufacturing, and commercialization progress. No revenue or earnings guidance was provided.
- Clinical progress and uncertainty: The head-and-neck cancer feasibility study had treated one patient and was recruiting additional patients. The COVID-19 study was designed for up to 40 patients at up to 20 U.S. centers; Aethlon reported site-readiness work with PPD and approvals or agreements involving Stanford and, after quarter-end, Medanta Hospital in India. Trial enrollment, timing, outcomes, and regulatory approval remain uncertain.
- Operational commitments: Aethlon entered a September 2021 agreement for PPD to oversee COVID-19 clinical studies; the agreement has a five-year term but may be terminated by Aethlon on 30 days’ notice without cause. A new office/lab lease was expected to begin upon occupancy, with estimated present-value payments of about $806,000. An October 2021 manufacturing-space lease was also disclosed, with initial base rent of $12,080 per month and anticipated occupancy in the second or third quarter of 2022.
- Other notable items: The filing reports $50,249 accrued for the former CEO’s separation agreement. Management cited COVID-19-related uncertainty for trial timelines, operations, and future access to capital, despite no significant disruption reported to date. The company noted risks from clinical and regulatory failure, manufacturing scale-up, competition, patent protection, reimbursement, and dependence on additional funding. It reported no pending or threatened legal proceedings and no off-balance-sheet arrangements.
- Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether clinical sites enroll patients as planned, and whether the cancer and COVID-19 studies produce safety or efficacy evidence sufficient to support regulatory progress.
- Whether the stated cash runway remains adequate as trial, manufacturing, facility, and staffing expenses develop; review subsequent cash burn and financing needs.
- The terms, remaining obligations, and cash impact of the office/lab and manufacturing leases, including occupancy timing and any associated restricted cash.
- Further dilution from outstanding options and warrants, and the company’s ability to raise capital without materially affecting existing shareholders.
- Timing and collectability of government-contract revenue, including milestone performance and amounts deferred when milestones are missed.